Pubblicazioni in Inglese su Riviste recensite su MedlineImpact factor
1.Gambi D., Rossini PM., Onofrj M., Marchionno L. Visual Evoked Cortical Potentials by television presentation of different patterned stimuli to patients with multiple sclerosis. It. J. Neurol. Sci., 1, 2: 101-106, 1980. 0.12
2.Onofrj M., Pinto F., Mancinelli R., Pola P. Frequency and luminance sensitivity of visual evoked responses in developing rats. Physiol. Behav., 25: 299-303, 1980. 2.4
3.Pinto F., Onofrj M., Mancinelli R., Garzetti GG., Masini L. Bellati U. A follow-up electrophysiological study of rats with poor intrauterine fetal growth: the development of visual evoked responses (VERs) Experientia, 37: 724-725, 1981. 1.86
4.Onofrj M., Bodis-Wollner I., Mylin LH. Visual Evoked Potential latencies in papilledema and hydrocephalus. Neuro- Ophthalmology, 2, 2: 85-92, 1981. 1.35
5.Scerrati M., Onofrj M., Pola P. Effects of spinal cord stimulation on spasticity: H-reflex study. Appl. Neurophysiol., 45: 62-67, 1982. 0.81
6.Onofrj M., Bodis-Wollner I., Bobak P. Pattern visual Evoked Potentials in the rats. Physiol. Behav., 28: 227-230, 1982. 2.4
7.Onofrj M., Bodis-Wollner I. Dopaminergic deficency causes delayed visual evoked potentials in rats. Ann. Neurol., 11: 484-490, 1982. 8.1
8.Onofrj M., Bodis-Wollner I., Mylin L. VEP diagnosis of field defects in patient with chiasmatic and retrochiasmatic lesions. J. Neurol. Neurosurg. Psychiat., 45: 294-302, 1982. 3.6
9.Onofrj M., Bodis-Wollner I., Pola P., Calvani M. Central cholinergic effect of L-Acetyl Carnitine. Drugs Exp. Clin. Res., 9: 161-168, 1983. 0.58
10.Harnoys C., Bodis-Wollner I., Onofrj M. The effect of contrast and spatial frequency on the visual evoked potentials of the hooded rat. Exp. Brain Res., 57: 1-8, 1984. 2.0
11.Onofrj M., Harnoys C., Bodis-Wollner I. The hemispheric distribution of the transient rat VEP: a comparison of flash and pattern stimulation. Exp. Brain Res., 59: 427-433, 1985. 2.0
12.Onofrj M., Basciani M., Treviso M., Uncini A. Recovery of VEP delay in patients with vitamin B12 deficiency. It. J. Neurol. Sci., 6: 491-493, 1985. 0.9
13.Onofrj M., Falsini B., D'Annunzio V., Basciani M. Treviso M. Pattern electroretinograms recorded simultaneously with VEPs by means of an inexpensive electrode. I.R.C.S. Med. Sci., 13: 227-228, 1985. 0.2
14.Scerrati M., Onofrj M., Pacifici L., Pola P., Ramacci MT., Rossi GF. Electrocerebral and behavioural analysis of systemic kainic acid- induced epilepsy in the rat. Drugs Exptl. Clin. Res., 2: 671-680, 1986. 1.0
15.ddball" paradgm. Electrenceph. Clin Neurophysiol., 65: 231-235, 1986. 2.3
16.Onofrj M., Ghilardi MF., Basciani M., Gambi D. Visual Evoked Potentials in Parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J. Neurol.Neurosurg. Psychiat., 49: 1150-1159, 1986. 3.6
17.Pinto F., Onofrj M., Pola P., Tempesta E, Torrioli M.G. Fetal Addiction to methadone: postnatal abstinence syndrome and development of visual evoked potentials. Drug and Alcohol Dependence, 18: 1-10, 1986. 3.2
18.Onofrj M., Bodis-Wollner I., Calvani M. Effect of L-Acetyl carnitine HCl on rat steady state VEPs. Comparision with L-Carnitine. Drugs Exptl. Clin. Res., 13: 5-13 1987. 1.0
19.Onofrj M., Ghilardi MF., Faricelli A., Bodis-Wollner I., Calvani M. Effect of Levo-Acetyl carnitine on P300 like potentials of the normal monkey. Drugs Exptl. Clin. Res., 13: 5-13, 1987. 1.0
20.Onofrj M., Basciani., Censoni AG., Gambi D. Serial recording of VEPs to different stimuli in multiple sclerosis patients. It. J. Neurol. Sci., 6: 113-119, 1987. 0.9
21.Ghilardi MF., Marx M.S., Onofrj M., Glover A., Bodis-Wollner I. Scalp distribution of pattern visual evoked potentials in normal and hemianopic monkeys. Physiol. Behav., 41: 297-302, 1987. 2.4
22.Ghilardi MF., Bodis-Wollner I., Onofrj M., Marx MS., Glover A. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain, III: 131-149, 1988. 7.6
23.Uncini A., Treviso M., Basciani M., Onofrj M., Gambi D. Associated Central and peripheral demyelination: an electrophysiological study. J. Neurol., 235: 238-240, 1988. 3.0
24.Ghilardi MF., Chung E., Bodis-Wollner I., Dvorzniak M., Glover A., Onofrj M. Systemic1-Methyl, 4-Phenyl, 1-2-3-6 tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci., 43: 255-262, 1988. 2.4
25.Glover A., Ghilardi MF., Bodis-Wollner I., Onofrj M. Alterations in event-related potentials (ERPs) of MPTP treated monkeys. Electroenceph. Clin. Neurophysiol., 71: 461-468, 1988. 2.3
26.Basciani M., Onofrj M. A simple system for vibrotactile tapping stimulation in neurophysiological investigations. Med. Sci. Res., 16: 1237-1238, 1988. 0.3
27.Gambi D., Onofrj M., Calvani M., Faricelli A., Del Re ML., Bazzano S., Cutarella R., Fulgente T., Colangelo U. Neurophysiological studies of Acetyl L Carnitine. Administration in man. Drugs Exptl. Clin. Res., 15: 960-972, 1989. 1.0
28.Uncini A., Onofrj M., Basciani M., Cutarella R., Gambi D. Orthostatic tremor: Report of two cases and an electrophysiological study. Acta Neurol. Scand., 79: 119-122, 1989. 1.8
29.Onofrj M., Gambi D., Malatesta G., Ferracci F., Fulgente T. Electrophysiological techniques in the assessment of aging brain: lacunar state and differential diagnosis. Eur. Neurol., 462: 1-5, 1989. 1.0
30.Nobilio D., Faricelli A., Colangelo U., Del Re ML., Bazzano S., Onofrj M., Gambi D. The effect of Levo-Acetyl-carnitine on P300 potentials. Curr. Therap. Res., 47, 2: 267-277, 1990. 0.3
31.Delacour J., Bassant MH., Onofrj M., Santucci V., Kleinlogel H. Electrophysiological models for the study of cognition enhancers. Pharmacopsychiat., 2, 23: 90-93, 1990. 2.8
32.Onofrj M., Basciani M., Fulgente T., Bazzano S., Malatesta G., Curatola L. Maps of somatosensory evoked potentials (SEPs) to mechanical (tapping) stimuli: comparison with P14, N20, P22, N30 of electrically elicited SEPs. Electroenceph. Clin. Neurophysiol., 77: 314-319, 1990. 2.3
33.Uncini A., Basciani M., Di Muzio A., Antonini D., Onofrj M. Methyl bromide myoclonus: an neurophysiological study of myoclonus due to Metylbromide intoxication. Acta Neurol. Scand., 81: 159-164, 1990. 1.8
34.Fulgente T., Onofrj M., Del Re ML., Ferracci F., Bazzano S., Ghilardi MF., Malatesta G. Laevo-Acetyl Carnitine (Nicetile) treatment of senile depression. Clin. Trial J., 27, 3: 155-163, 1990. 0.28
35.Onofrj M., Ghilardi MF. MPTP induced Parkinsonian syndrome: long term follow-up and neurophysiological study. It. J. Neurol. Sci., 11: 445-458, 1990. 0.9
36.Onofrj M., Ghilardi MF., Basciani M., Martinez-Tica J., Glover A. Attenuation of the early anterior negativity of median nerve somatosensory evoked potentials in the MPTP-treated monkeys. Neurophysiol. Clin., 20: 283-293, 1990. 1.0
37.Onofrj M., Bazzano S., Malatesta G., Gambi D. Patophysiology of delayed evoked potentials in multiple sclerosis. Funct. Neurol., V, 4: 301-319, 1990. 0.6
38.Onofrj M., Bazzano S., Malatesta G., Fulgente T. Mapped distribution of pattern reversal VEPs to central field and lateral half-field stimuli of different spatial frequencies. Electroenceph. Clin. Neurophysiol., 80: 167-180, 1991. 2.3
39.Visual "cognitive" Evoked Potentials in the behaving monkeys. Electroenceph. Clin. Neurophysiol. 80(1): 65-72, 1991. 2.3
40.Ghilardi MF., Sartucci F., Brannan JR., Onofrj M., Bodis-Wollner I, Mylin L., Stoch R. N70 and P300 can be independently affected in multiple sclerosis. Electroenceph. Clin. Neurophysiol., 80: 1-7,1991. 2.3
41.Onofrj M., Fulgente T., Nobilio D., Bazzano S., Colamartino P. Mapping of event related potentials to auditory and visual oddball paradigms in controls. Eur. Neurol., 31: 220-228, 1991. 1.0
42.Onofrj M., Gambi D., Del Re ML., Fulgente T., Bazzano S., Colamartino P., Malatesta G. Mapping of event related potentials to auditory and visual oddball paradigms in patients affected by different forms of dementia. Eur. Neurol., 31: 259-269, 1991. 1.0
43.Onofrj M., Curatola L., Malatesta G. Bazzano S., Colamartino P., Fulgente T. Reduction of P3 latency during outcome from post-traumatic amnesia. Acta Neurol. Scand., 83: 273-279, 1991. 1.8
44.Onofrj M., Gambi D., Fulgente T., Bazzano S., Colamartino P. Persistence of P3 component in severe Amnestic Syndrome. Electroenceph. Clin. Neurophysiol., 78: 480-484, 1991. 2.3
45.Bodis-Wollner I., Chung E., Ghilardi MF., Glover A., Onofrj M., Pasik P., Samson Y. Acetyl-levo-carnitine protects against MPTP-induced parkinsonism in primates. J. Neural Trasm., 3: 63-72, 1991. 2.9
46.Uncini A., Gallucci M., Lugaresi A., Porrini AM., Onofrj M., Gambi D. CNS involvement in chronic infiammatory polyneuropathy. An electrophysiological and MRI study. Electromyogr. Clin. Neurophysiol., 31: 365-371, 1991. 0.0
47.Onofrj M., Gambi D., Bazzano S., Colamartino P., Fulgente T., Malatesta G., Ferracci F. Evoked Potentials (EPs) in Experimental Allergic Encephalomylitis: a study of EP modifications during the course of a controlled disease. Electromyogr. Clin. Neurophysiol., 32:125-135, 1992 0.0
48.Onofrj M., Curatola L., Malatesta G., Colamartino P., Bazzano S., Fulgente T., Ferracci F. Delayed P3 Event Related Potentials (ERPs) in Thalamic Hemorrhage. Electroenceph. Clin. Neurophysiol., 83:52-61, 1992. 2.7
49.Onofrj M., Fulgente T., Nobilio D., Malatesta G., Bazzano S., Colamartino P., Gambi D P3 recordings in patients with bilateral temporal lobe lesions. Neurology, 42 (9):1762-
1767, 1992. 		5.7
50.Onofrj M., Curatola L., Ferracci F., Fulgente T. Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject. Jour. Neurol. Neurosurg. Psychiat., 55:852- 853, 1992 3.6
51.Caraceni T., Musicco M., ..... Onofrj M., et al. A multicenter italian randomised study on early treatment of Parkinson disease: comparison of l-dopa, l-deprenyl and dopaminoagonists. Study design and short term results. Ital.J.Neurol.Sci.,13:735-739, 1992. 0.9
52.Onofrj M., Fulgente T., Gambi D., Macchi G. Early MRI findings in Creutzfeldt-Jakob disease. Jour. Neurol., 240:423-426, 1993 3.0
53.Onofrj M., Fulgente T., Malatesta G., Ferracci F. Visual Evoked Potentials (VEPs) to altitudinal stimuli: effects of stimulus manipulations on VEP scalp topography. Clin. Vision Sci., Vol.8 (6):529-544, 1993 1.3
54.Tartaro A., Fulgente T., Delli Pizzi C., Bonomo L., Bocola V., Onofrj M. MRI alterations as an early finding in Creutzfeldt- Jakob disease. Eur. J. Radiol., 17: 155-158, 1993 1.3
55.Onofrj M., Ferracci F., Fulgente T., Malatesta G., Ghilardi M.F. Effects of drug manipulations on anterior components of somatosensory evoked potentials in parkinsonian animal model.Drugs Exptl. Clin. Res., Vol.20 (1):29-36, 1994 1.0
56.Onofrj M., Fulgente T., Malatesta G., Locatelli T. Focal abnormalities of P3 ERPs unveiled in patients with cortical lesions and primary progressive aphasia by average reference recordings. Brain Topography, 6(4): 311-322, 1994 (IF dal 1999 - 1.50) 1.4
57.Onofrj M., Fulgente T., Thomas A., Peresson M., Locatelli T., Martinelli V., Comi G. Source model and scalp topography of pattern reversal Visual Evoked Potentials (VEPs) to altitudinal stimuli suggested that infoldings of calcarine fissure are not part of VEP generators. Brain Topography, 3:217-231,1995 (IF dal 1999 - 1.50) 1.4
58.Tartaro A., Onofrj M., Thomas A., Fulgente T., Delli Pizzi C., Bonomo L. Long Time Echo STIR Sequence Magnetic Resonance Imaging of Optic Nerves in Optic Neuritis. Eur. J. Radiol., 19:155-163, 1995 1.3
59.Fulgente T, Thomas A, Lobefalo L, Mastropasqua L, Gallenga PE, Gambi D, Onofrj M. Are VEP abnormalities in optic neuritis (ON) Dependent on plaque size? A reappraisal of the physiopathology of ON based on improved MRI and multiple-lead recordings. Ital. J. Neurol. Sci., 43-54, 1995 0.9
60.Tartaro A, Onofrj M, Delli Pizzi C, Bonomo L, Thomas A, Fulgente T, Gambi D. Long time echo STIR sequence magnetic resonance imaging of optic nerves in Optic neuritis.Ital. J. Neurol. Sci., 35-42, 1995 0.9
61.Onofrj M, Fulgente T., Melchionda D., Marchionni A., Tomasello F., Salpietro FM., Alafaci C., De Sanctis E., Pennisi G., Ventura F., Morganti A. L-Acetylcarnitine as a new therapeutic apphroach for peripheral neuropaties with pain. Int. J. Clin. Pharm. Res., XV (1):17-22, 1995 0. 6
62.Onofrj M., Fulgente T., Malatesta G., Thomas A., Locatelli T., Comi G. P300 asymmetries in focal brain lesions are reference dependent. Electroenceph. Clin. Neurophysiol., 94: 432-439, 1995 2.27
63.Onofrj M., Fulgente T., Malatesta G., Ferracci F., Thomas A., Curatola L., Bollettini F., Ragno M. The abnormality of N30 somatosensory evoked potential in idiopathicParkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations. Movement Disorders, Vol. 10, No 1 pp71-80, 1995 3.3
64.Onofrj M., Fulgente T., Thomas A., Peresson M., Lopez L., Locatelli T., Martinelli V., Comi G. Visual Evoked Potentials generator model derived from different spatial frequency stimuli of visual field regions and magnetic resonance imaging coordinates of V1, V2, V3 areas in man. Int. J. Neuroscience, 83: 213-239; 1995 (rivista pubblicata dal 1982 al 1995) 0.8
65.Onofrj M., Curatola L., Valentini G.L., Antonelli M., Thomas A., Fulgente T. Non dominant dorsal-prefrontal activation during chess problem solution evidenced by single photon emission computerized tomography (SPECT). Neuroscience Letters,198: 169-172, 1995 2.1
66.Onofrj M., Fulgente T., Thomas A. Event related potentials recorded in dorsal simultanagnosia. Cognitive Brain Research, 3:25-32, 1995 2.3
67.Gambi D., Fulgente T., Melchionda D., Onofrj M. Evoked Potential (EP) Alterations in Experimental Allergic Encephalomyelitis (EAE): Early Delays and Latency Reductions Without Plaques. Ital. J. Neurol. Sci., 23-34, 19960.9
68.Onofrj M, Thomas A, Melchionda D. Brain Water Intoxication and CT scan Hypolucencies in Ovarian Hyperstimulion SyndromeComplicating Gametes Intra- Fallopian Transfer (GIFT) and Tubaric Pregnancy. J.Neurol.Neurosur. Psychiatry 60:233- 234, 1996 3.6
69.Onofrj M., Tartaro A., Thomas A., Gambi D., Fulgente, T., Delli Pizzi C., Bonomo L. Long time echo STIR sequence Magnetic Resonance Imaging of optic nerves in opticneuritis. Neuroradiology, 1996, 38:66-69 1.6
70.Onofrj M, Melchionda D, Thomas A, Fulgente T. Reappearance of event related p3 potential in locked-in syndrome. Cogn. Brain Research, 4:95-97, 1996 2.3
71.Onofrj M, Fulgente T, Thomas A, Gambi D. Delayed and pseudodelayed VEPs in opticneuritis (ON) compared with long time echo STIR MRI of optic nerves. Electroenceph. Clin. Neurophysiol. 100: 275-286, 1996 2.47
72.Sabatino G, Verrotti LA, Ramenghi S, Domizio S, Melchionda D, Fulgente T, Paci C, D’Andreamatteo G,Thomas A, Onofrj M. Newborns with hyperbilirubinemia: usefulness of brain-stem auditory response evaluation. Neurophysiologie Clinique, 26:363-368,1996 1.0
73.Caraceni A, Martini C., Spatti G., Thomas A., Onofrj M. Recovering optic Neuritis during systemic cisplatin and carboplatin chemiotherapy. Acta Neurol Scand.1997, 96: 260-261 1.8
74.Onofrj M., Thomas A., Paci C, Scesi M., Tombari R. Event related potentiales (ERPs) recorded in patients with locked-in syndrome (LIS). J Neurol Neurosurg Psychiatry 1997, 63: 759-764 3.6
75.Onofrj M, Thomas A, Paci C, D’Andreamatteo G. Gabapentin in orthostatic Tremor: results of a double blind cross-over with placebo in 4 patients. Neurology 51 Sep Vol. 51: 880-882, 1998 5.7
76.Onofrj M, Thomas A, Paci C. Reversible Parkinsonism induced by prolonged treatment with Valproate. J Neurol, 245:794-796,1998 3.0
77.Onofrj M, Paci C, Thomas A. Sudden appearence of invalidanting dyskinesia-dystonia and off-fluctuations after the introduction of L-Dopa in two dopamimetic drugs naive stage IV Parkinson’s Disease patients. J Neurol Neurosurg Psychiat Vol 65 n. 4 pag 605-606, 1998 3.6
78.Onofrj M, Thomas A, Paci C, Rotilio D. Optic Neuritis with residual Tunnel Vision in perchloroethilene toxicity. J. Toxicol. Clin. Tox.icol 36 (6) 603-607, 1998 2.0
79.De Feo MR, Mercarelli O, Marciani MG, Striano S, Tata MR, D’Alesandro PD, Cerone G, Ortenzi A, Onofrj M. Vigabatrin monotherapy in newly diagnosed partieal epilepsy: an open multicentre Italian pilot study. Med Sci Res , 283-284, 1998 0.3
80.Melchionda D, Verrotti A, Chiarelli F, Domizio S, Sabatino G, Mucedola T, D’Andreamatteo G, Toma L, Di Iorio A, Onofrj M. Headache in children with centro-temporal spikes. Neurophysiol Clin. 1999; 90-100 1.0
81.Onofrj M, Thomas A, Paci C, D’Andreamatteo G, Toma L, Rotilio D. Optic Neuritis with residual tunnel vision in perchloroethilene toxicity. Eur Neuro1999, 51-53 1.0
82.Onofrj M and Thomas A. Acetazolamide Responsive Periodic Ataxia induced by Amiodarone. Mov. Disord. March 14(2):379-381,1999 3.3
83.Thomas A and Onofrj M. Sporadic Acetazolamide Responsive Episodic Ataxia. Mov. Disord. 14:6:10551056;1999 3.3
84.A. Verotti, S. Domizio, D. Melchionda, M. Guerra, T. Mucedola, M. Onofrj, F. Chiarelli, G. Sabatino. Stormy Onset in benign childhood epilepsy with occipital paroxysmal discharges. Child’s Nervous System 1999 1.3
85.Onofrj M, Paci C, D’Andreamatteo G, Toma L. Olanzapine in severe Gilles della Tourette Syndrome (GTS): cross over vs pimozide. J. Neurol 247:443-446;2000 3.0
86. Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Leucopenia induced by low dose clozapine in Parkinson’s Disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. Neurol Sci 2000, 21:209-215 0.9
87. Pagano F, Impagnatiello F, Girelli M, Cova L, Grioni E, Onofrj M, Cavallaro M, Etteri S, VitelloF, Solero CL, Giombini S, Parati EA. Isolation and characterization of neural stem cells from the adult human olfactory bulb. Stem Cells 18(4):295-300; 2000 7.9
88. Onofrj M, Thomas A, Iacono D, D’Andreamatteo G, Paci C. Age-related changes of evoked potentials. Neurophisol Clin, 2001; 31:83-101 1.0
89. Onofrj M, Thomas A. One further case of pancytopenia induced by Olanzapine in a Parkinson’s Disease patient. Eur Neurology 2001;45:56-57 1.35
90. Onofrj M, Thomas A, Di Iorio A, Iacono D, Bonanni L Switch-over from Tolcapone to Entacapone in severe Parkinson’s Disease patients. Eur Neuro, 2001;46:11-16 1.0
91. S.F.Pagano, S.Lucchiari, A.Bez, D.Ponti, M.Onofrj,F.Vitello, Y.Torrente, V.Di Giorgi, S.Etteri, N.Bresolin, A Colombo, M Girelli, L.Cova and E.A.Parati. The role of Interleukine-6 (IL-6) in the proliferation and differentiation of Human Neural Stem Cells. Neurosci. Res. Comm. 2001; 29 (1):1-14. 0.3
92. Thomas A, Iacono D, Bonanni L, D’Andreamatteo G, Onofrj M. Donepezil, Rivastigmine and Vitamine E in Alzheimer’s Disease: a combined P300 event related potentials-neurophysiologic test evaluation over 6 months. Clin Neuropharmacology 2001, 24(1):31-42 2.45
93. Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A, D’Andreamatteo G, Di Iorio A. Donepezil vs Vit E in Alzheimer’s disease (AD), part 2: mild vs moderate-severe AD. Clinical Neuropharmacology 2002;45 :207-215 2.3
94. Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Leucopenia induced by low dose clozapine in Parkinson’s disease recedes shortly after drug withdrawal. Review series Psychiatry 2002;2:22-24 0.83
95. Onofrj M, Thomas A, D’Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, Di Mascio R, Ballone E, Di Iorio A. Incidence of RBD and hallucination in patients affected by
Parkinson’s Disease: 8 years follow-up. Neurol Sci 2002, 23:91-94.		0.9
96. Stocchi F., Vacca L, Berardelli A., Onofrj M., Ruggeri S., Dual dopamine agonist treatment in Parkinson’s desease J. Neurology 2003 Jul, 250 (7); 822-6 2.8
97. M Onofrj, A Thomas, D Iacono, AL Luciano, A Di Iorio The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition A part 3 study of the main mechanism of cholinesterase inhibitors in dementia . Clin Neuropharmacol 2003, 26(5):239-251 2.3
98. Onofrj M, Luciano AL, Iacono D, Thomas A, Stocchi F, Papola F, Adorno D, Di Mascio R. HLA typing does not predict REM Sleep Behaviour Disorder and hallucinations in Parkinson’s Disease. Mov Disord 2003 :18 :337-349. 3.3
99. M. Onofrj, A.L. Luciano, A. Thomas, D. Iacono; G. D’Andreamatteo, Mirtazapine induces REM sleep behaviour disorder (RBD) In Parkinsonism. Neurology 2003; 60:113-115 5.7
100. A Thomas, D. Iacono, AL Luciano, K. Armellino M Onofrj.Akinetic syndrome in Parkinson’s Disease. Neurol Sci 2003,24:219-220 0.9
101. F. Stocchi, L. Vacca, P. Grassini, G. Battaglia, M. Onofrj, M. Valente, S. Ruggieri. Optimizing levodopa pharmacokinetics in Parkinson’s Disease: the role of COMT inhibitor. Neurol Sci 2003,24:217- 218 0.9
102. Onofrj M and Thomas A. Severe worsening of Parkinsonism in Lewy Body Dementia due to Donepezil. Neurology 2003, 25;61(10):1452. 5.7
103. Onofrj M and Thomas A Reply. Mirtazapine induces REM sleep behaviour disorder (RBD) In Parkinsonism. Neurology 2003; 61(8); 1161 5.7
104. A Thomas, D Iacono, AL Luciano, K Armellino, M Onofrj. Duration of Amantadine benefit on dyskinesias of severe Parkinson’s Disease. J Neurol Neurosurg Psychatry 2004,75(1):141-3 3.6
105. M Onofrj, A Thomas, F Vingerhoets, W Martin, S Gimenez, J-P Azulay Combining entacapone with levodopa/DDCI improves clinical status in Parkinson’s disease (PD) patients experiencing ‘end-of-dose wearing-off’, regardless of the dosing frequency: Results of a multicenter open-label study J Neurol Tras 2004;111(8):1053-63. 2.9
106. M Onofrj, D Iacono, AL Luciano, K Armellino, A Thomas, Unilateral dissociation of saccades and pursuit eye movement due to medial thalamic lesion. J Neurol Neurosurg Psychatry 2004 3.6
107. Stocchi F, Arnold G, Onofrj M, Kwiecinski H, Szczudlik A, Thomas A, Bonucelli U, Van Dijk A, Cattaneo C, Sala P, Fariello RG for the Safinamide Parkinson’s Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63:746-748 5.7
108. Onofrj M and Thomas A. Which motor symptoms worsen during cholinesterase treatment. Neurology ; 5.7
109. Parati EA. Pozzi S. Ottolina A. Onofrj M. Bez A. Pagano SF Neural stem cells: an overview J. Endocrinol Invest. 2004; 27 (6 Suppl):64-7. Review. 1.5
110. Onofrj M and Thomas A. Acute Akinesia in Parkinson’s Disease. Neurology 2005, Aprile :64:1162-1169 5. 7
111. Thomas A., M. Onofrj Akinetic crisis, acute akinesia, neuroleptic malignant-like syndrome, Parkinsonism-hyperpyrexia syndrome, and malignant syndrome are the same entity and are often indipendent of tratment withdrawal. Mov. Disord. 2005 Dec;20(12)3.3
112. Franciotti R. Iacono D. Della Penna S. Pizzella V. Torquati K. Onofrj M. Romani GL. Cortical rhythmus reactivity in AD, LBD and normal subjects: a quantitative MEG study. NEUROBIOL Aging. 2006 Aug; 27 (8): 1100-9. Epub 2005 Aug 1 5.6
113. Poewe W. Wolters E. EMRE m. Onofrj M. Hsu C. Tekin S. Lane R; EXPRESS Investigators Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension stady. Mov Disord. 2006 Apr; 21(4): 456-61 3.3
114. Di Fonzo A. Tassorelli C. De Mari M, Chien HF, Ferriera J, Rohe CF, Riboldazzi G, Antonimi A, Albani G. Mauro A, Marconi R, Abr5uzzese3 G. Lopiano L., Fincati E, Guidi M, Marini P, Stocchi F. Onofrj M, Toni v, Tonazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leinter P, Utti RJ, Wszolek ZK, Gasser T, Simons EJ Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Ostra BA, Bonifati V, Italian Parkinson’s Genetics Network. Comprensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet. 2006 Mar; 14(3): 322-31 3.7
115. Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson’s disease: clues to separate origins. J Neurol Sci. 2006 Oct 25;248 (1-2): 143-50 Expert Rev Neurother.2.50
116. Thomas A, Bonanni L, Di Iorio A, Varanese S, Anzellotti F, D’Andreagiovanni A, Stocchi F, Onofrj M. End-of-dose deteration in non ergolinic dopamineagonist monotherapy of Parkinson’s disease. J Neurol 2006 Dec; 253 (12): 1633-93.0
117. Bonanni L, Thomas A, Onofrj M, Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium Neurology. 2006 May 9,66 (9): 1455 author reply 1455. 5. 7
118. Bonanni L, Thomas A, Scorrano V, Onofrj M. Task-specific lower lip distonia due to mantra recitation. Mov. Disord. 2007 Feb 15;22(3): 439-40 3.3
119. Thomas A, Bonanni L, Onofrj M. Symptomatic REM sleep behaviour disorder. Neurol Sci. 2007 Jan; 28 Suppl 1:S21-36 0.9
120. Perfetti B, Franciotti R, Della Penna S, Ferretti A, Caulo M, Romani GL Low-and high-frequency evoked responses following pattern reversal stimuli: A MEG study supported by fMRIconstraint Neuroimage. 2007 Apr 15;35 (3): 1152-1167; Epub 2007 Feb 75.6
121. Bonanni Laura, Anzellotti Francesca, Varanese Sara, Thomas Astrid, Manzoli Lamberto, Onofrj Marco Delayed blink reflex in Lewy Bodies Dementia J. Neurology Neurosurgery Psychiatry 2007 Oct; 78(10):1137-93.6
122.Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Lane R.A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007 May;22(5):456-67. 2.0
123. Thomas A, Bonanni L, Antonini A, Barone P, Onofrj M Dopa-responsive pseudo-orthostatic tremor in parkinsonism Mov. Dis. 2007 Movement. Disorders. 2007 Aug 15; 22(11) : 1652-63.3
124. Bonanni L.Thomas A,Varanese S., Scorrano V., Onofrj M. Botulinum toxin treatment of Lateral Axial Distonia in Parkinsonism. Movement. Disorders. 2007 Oct 31; 22(14) : 2097-1033.3
125.Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Expert Rev Neurother. 2007 Dec;7(12):1731-50. Review.3.0
125.Perfetti B, Saggino A, Ferretti A, Caulo M, Romani GL, Onofrj M. Neuron underpinning of individual differences in fluid intelligence as a function of reasoning complexity: a functional Magnetic Resonance Imaging study. Human Brain Mapping 2007 Dec 19; 4.8
126. M. Onofrj An expert opinion on safinamide in Parkinson’s disease. Expert Opin Investig Drugs. 2008 Jul;17(7):1115-25. Review.3.2
127. A. Antonini P. Barone, M. Onofrj, M. Zappia, A. Quattrone. COMT inhibition with tolcapone in the treatment algorithm of patients wuth Parkinson’s disease (PD) relevance for motor and non-motor feautures. Neuropsychiatr Dis Treat. 2008 Feb;4(1):1-9.--
128. Laura Bonanni, Astrid Thomas, Pietro Tiraboschi, Bernardo Perfetti, Sara Varanese, Marco Onofrj. EEG comparison in early AD, DLB, PDD patients with a 2 years follow-up. Brain 2008 Mar; 131 (Pt 3) : 690-705. Epub 2008 Jan 179.0
129.Piazzini A, Beghi E, Turner K, Ferraroni M; LICE Quality of Life Group.Health-related quality of life in epilepsy: findings obtained with a new Italian instrument. Epilepsy Behav. 2008 Jul;13(1):119-26. Epub 2008 Apr 8.1.1
130.Invernizzi F, Varanese S, Thomas A, Carrara F, Onofrj M, Zeviani M. Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism.Neuromuscul Disord. 2008 Jun;18(6):460-4. Epub 2008 May 27. 2.3
131.Reale M, Iarlori C, Thomas A, Gambi D, Perfetti B, Di Nicola M, Onofrj M. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2008 Jul 17. [Epub ahead of print] 2009, 23:55-634.2
132. F Anzellotti, L. Bonanni, A. Thomas, E. Iorio, M. Onofrj Delayed blink reflex in lewy bodies dementia is sensitive to cholinergic modulation. Clinical Neuropharmacology 2008; 31(4): 231-72.1
 133. Stocchi, F...Onofrj M., Ease-PD Monotherapy Study Investigators. Ropinerole 24 hour prolonged releaseand ropinerole immediate release in  early Parkinson Disease:a randomized double blind non inferiority study.Curr Med Res ,2008,24:2883-95 3.3
 134. DI fonzo A ..Onofrj M..Oostra BA,Bonifati V.GIGYF mutations are not a frequent cause of familial Parkinson Disease.Park Relat Dis 2009 Epub. 2.7
 135.Pre-analytical factors in clinical proteomics investigations: Impact of ex vivo protein modifications for multiple sclerosis biomarker discovery. Pieragostino D, Petrucci F, Del Boccio P, Mantini D, Lugaresi A, Tiberio S, Onofrj M, Gambi D, Sacchetta P, Di Ilio C, Federici G, Urbani A. J Proteomics. 2009 Aug 8. [Epub ahead of print] PMID: 19666151 [PubMed - as supplied by publisher] -
 136.Behavioural assessment of dysexecutive syndrome in Parkinson's disease without dementia: A comparison with other clinical executive tasks. Perfetti B, Varanese S, Mercuri P, Mancino E, Saggino A, Onofrj M. Parkinsonism Relat Disord. 2009 Aug 6. [Epub ahead of print] PMID: 19665420 [PubMed - as supplied by publisher]2.7

Ultimo aggiornamento ( Mercoledì 04 Novembre 2009 16:23 )